{"id":"idea-033","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IDEA-033 works by binding to the molecular target, which results in the desired therapeutic effect. This mechanism of action is still being researched and more information is needed to fully understand how it works.","oneSentence":"IDEA-033 is a small molecule drug that targets the molecular target.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:30.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT00372333","phase":"PHASE3","title":"IDEA-033 Open Label Study","status":"COMPLETED","sponsor":"IDEA AG","startDate":"2004-08","conditions":"Joint Pain, Musculoskeletal Pain, Stiffness","enrollment":491},{"nctId":"NCT00317733","phase":"PHASE2","title":"Ketoprofen in Transfersome Compared to Oral Celecoxib and Placebo for Pain Associated With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"IDEA AG","startDate":"","conditions":"Osteoarthritis, Knee","enrollment":360},{"nctId":"NCT00316784","phase":"PHASE3","title":"IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA","status":"COMPLETED","sponsor":"IDEA AG","startDate":"2005-07","conditions":"Osteoarthritis; Knee","enrollment":704},{"nctId":"NCT00211549","phase":"PHASE2","title":"An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"IDEA AG","startDate":"2005-06","conditions":"Osteoarthritis, Knee","enrollment":875},{"nctId":"NCT00265304","phase":"PHASE2","title":"A Long-Term Safety Study of IDEA-033 in Comparison to Oral Naproxen for the Treatment of Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"IDEA AG","startDate":"2005-07","conditions":"Osteoarthritis, Knee","enrollment":550}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IDEA-033","genericName":"IDEA-033","companyName":"IDEA AG","companyId":"idea-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IDEA-033 is a small molecule drug that targets the molecular target. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}